Journal of Pharmaceutical Policy and Practice最新文献

{"title":"Assessing determinants of the availability of HIV tracer commodities in health facilities in Wakiso District, Uganda.","authors":"Falisy Lule, Kalid Rajab, Stany Banzimana, Domina Asingizwe","doi":"10.1080/20523211.2024.2306846","DOIUrl":"10.1080/20523211.2024.2306846","url":null,"abstract":"<p><strong>Background: </strong>HIV/AIDS commodity stock-outs are still rampant in most African Countries causing treatment interruption, antiretroviral resistance, treatment failure, morbidity and mortality. Therefore, this study aimed at assessing the determinants of the availability of HIV Tracer Commodities in Health Facilities in Wakiso District, Uganda.</p><p><strong>Methods: </strong>A descriptive cross-sectional design was conducted in 42 Health Facilities [HFs] offering HIV/AIDs services in Wakiso District, Uganda. Semi-structured questionnaire adapted from the Anti-Retroviral Therapy Supervision Performance and Recognition Strategy [ART SPARS] tool Version 2.0 | 2018111 was used to collect data.</p><p><strong>Results: </strong>The majority of the HFs 28 [67%] had all the seven tracer commodities on the day of the visit. The majority of the HFs 33 [78.6%] were using Manual stock management tools that were fully updated. The availability of HIV tracer commodities was high in facilities that made timely ordering [AOR: 2.538, 95% CI: 2.126-3.304, <i>p</i>-value = 0.003] while the use of manual LMIS alone at the facility [AOR: 0.623, 95% CI: 0.131-0.958, <i>p</i>-value = 0.002] was associated with low availability.</p><p><strong>Conclusion: </strong>This study indicated that 67% of health facilities visited had all HIV Tracer commodities on the day of the visit. ART commodity management should be computerised and orders made on time to ensure the availability of commodities.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139707008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus guidelines for community pharmacists in the management of diabetic peripheral neuropathy with a combination of neurotropic B vitamins.","authors":"Thanompong Sathienluckana, Sirinoot Palapinyo, Kitiyot Yotsombut, Ekgaluck Wanothayaroj, Pasiri Sithinamsuwan, Naeti Suksomboon","doi":"10.1080/20523211.2024.2306866","DOIUrl":"10.1080/20523211.2024.2306866","url":null,"abstract":"<p><p>This consensus guidance is for community pharmacists in diabetic peripheral neuropathy (DPN) management with a combination of neurotropic B vitamins. A multidisciplinary team including endocrinology, neurology, and pharmacy from Thailand discussed and aligned the practical scheme of DPN management in the community pharmacy setting, using the literature review and having face-to-face meeting. Five major statements have been endorsed as consensus recommendations for DPN care with strong acknowledgment. The aims of DPN management included reducing symptoms and the risk of complications, minimising adverse reactions from treatment regimens, and improving patients' knowledge and adherence to the treatment strategies. An initial screening process using a 7 items interview of Douleur Neuropathique 4 (DN4) questionnaire should be implemented to identify patients at risk of developing DPN. Subsequently, pharmacologic, and non-pharmacologic treatment should be employed based on patient-centered care. An interesting approach is combination of neurotropic B vitamins, which may be used as monotherapy or combination therapy to control DPN symptoms. The combined therapy potentially exhibits a synergistic effect and improves patient adherence. The consensus would be further considered in context of harmonisation of routine practice and country requirements.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmaceutical systems strengthening through the lens of Tony Boni – a tribute","authors":"Jude Nwokike, Maria Miralles, Douglas Keene, Patrick Lukulay, Alison Collins, Elizabeth Ludeman, Tobey Busch, Francis Aboagye-Nyame, David Lee Chin","doi":"10.1080/20523211.2024.2305775","DOIUrl":"https://doi.org/10.1080/20523211.2024.2305775","url":null,"abstract":"ABSTRACT With clarity of vision and ability to navigate complex government bureaucracy, Anthony (Tony) Boni built an enduring legacy in pharmaceutical systems strengthening.","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139598419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A qualitative study exploring community pharmacists' awareness, attitudes and perceptions about drive-thru community pharmacy service in Malaysia during COVID-19.","authors":"Bayan F Ababneh, Siew Chin Ong, Iffat Elbarazi, Hisham Z Aljamal, Rabia Hussain","doi":"10.1080/20523211.2024.2303752","DOIUrl":"10.1080/20523211.2024.2303752","url":null,"abstract":"<p><strong>Introduction: </strong>Drive-thru services are not given sufficient focus in the community pharmacy setting which was highlighted during COVID-19, particularly in Malaysia. This study aimed to explore the community pharmacists' perspectives regarding drive-thru community pharmacy service during COVID-19 in Malaysia.</p><p><strong>Methods: </strong>In-depth online semi-structured individual interviews were conducted among 25 community pharmacists working in Malaysia. All interviews were conducted between March 2022 and May 2022 and were audio-recorded and transcribed verbatim, and then analysed by thematic analysis.</p><p><strong>Results: </strong>Thematic analysis yielded seven major themes, 1-familiarity with drive-thru community pharmacy service during COVID-19, 2-willingness toward this service during COVID-19, 3-perceived benefits toward drive-thru community pharmacy service during COVID-19, 4-perceived disadvantages toward this service, 5-barriers toward drive-thru community pharmacy service, 6-factors affecting the preference toward this service, and 7-facilitators to drive-thru community pharmacy service. Enhancing social distancing and preventing the spread of COVID-19 were the major perceived benefits of this service during COVID-19 as reported by participants.</p><p><strong>Conclusion: </strong>Overall, community pharmacists reported positive attitudes toward drive-thru community pharmacy service during COVID-19. However, concerns about poor communication between the pharmacist and the patient, limited counselling, and dispensing errors were acknowledged. These concerns would need to be addressed to improve the provision of drive-thru community pharmacy service.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10802799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139521253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of community and hospital pharmacist involvement in outpatient chemotherapy using Japanese health information data","authors":"Mari Iwata, M. Maezawa, Koumi Miyasaka, S. Hirofuji, Takaaki Suzuki, Satoshi Nakao, Hirofumi Tamaki, Nanaka Ichihara, Yuka Nokura, M. Masuta, Hiroaki Uranishi, Yuri Nishibata, K. Iguchi, Mitsuhiro Nakamura","doi":"10.1080/20523211.2023.2286350","DOIUrl":"https://doi.org/10.1080/20523211.2023.2286350","url":null,"abstract":"","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139616167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution.","authors":"Maria Inês Teodoro, Alexandra Mayer, Ana da Costa Miranda, Hugo Nunes, Filipa Alves da Costa, António Lourenço","doi":"10.1080/20523211.2023.2296551","DOIUrl":"10.1080/20523211.2023.2296551","url":null,"abstract":"<p><strong>Background: </strong>Monotherapy with aromatase inhibitors and fulvestrant were the standard-of-care for hormone receptor-positive (HR+)/human epidermal growth factor receptor-type2 negative (HER2-) advanced breast cancer, before integration of cyclin-dependent kinase 4/6 inhibitors. Effectiveness data is essential for regulatory action, but little is known about real-world use of aromatase inhibitors and fulvestrant.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted resorting to data from a cancer registry to identify adult women with HR+/HER- advanced breast cancer exposed to aromatase inhibitors or fulvestrant (31 May 2017-31 March 2019) at the main oncology hospital in Portugal. Cases were updated with follow-up until death or cut-off (31 March 2021) and pseudoanonymized data extracted. Primary outcome was overall survival (OS) and secondary time to treatment failure (TTF), estimated using survival analysis and compared with published trials.</p><p><strong>Results: </strong>192 patients were distributed by subgroups according to the medicine. Letrozole: OS 30.8 (95% confidence interval (CI) 20.6-41.4); TTF 11.2 (95%CI 8.7-13.7). Exemestane: OS 22.1 (95%CI 9.7-34.6); TTF 6.0 (95%CI 4.1-7.8). Fulvestrant: OS 21.6 (95%CI 16.5-26.7); TTF 5.6 (95%CI 4.5-6.6).</p><p><strong>Conclusions: </strong>Estimated effectiveness (OS) of letrozole and fulvestrant was, respectively, 3.2-3.5 months lower than reported. The clinical meaning seems uncertain and may be explained a higher proportion of worse prognostic characteristics in patients treated in the real-world.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detecting manuscripts written by generative AI and AI-assisted technologies in the field of pharmacy practice.","authors":"Ammar Abdulrahman Jairoun, Faris El-Dahiyat, Ghaleb A ElRefae, Sabaa Saleh Al-Hemyari, Moyad Shahwan, Samer H Zyoud, Khawla Abu Hammour, Zaheer-Ud-Din Babar","doi":"10.1080/20523211.2024.2303759","DOIUrl":"10.1080/20523211.2024.2303759","url":null,"abstract":"<p><p>Generative AI can be a powerful research tool, but researchers must employ it ethically and transparently. This commentary addresses how the editors of pharmacy practice journals can identify manuscripts generated by generative AI and AI-assisted technologies. Editors and reviewers must stay well-informed about developments in AI technologies to effectively recognise AI-written papers. Editors should safeguard the reliability of journal publishing and sustain industry standards for pharmacy practice by implementing the crucial strategies outlined in this editorial. Although obstacles, including ignorance, time constraints, and protean AI strategies, might hinder detection efforts, several facilitators can help overcome those obstacles. Pharmacy practice journal editors and reviewers would benefit from educational programmes, collaborations with AI experts, and sophisticated plagiarism-detection techniques geared toward accurately identifying AI-generated text. Academics and practitioners can further uphold the integrity of published research through transparent reporting and ethical standards. Pharmacy practice journal staffs can sustain academic rigour and guarantee the validity of scholarly work by recognising and addressing the relevant barriers and utilising the proper enablers. Navigating the changing world of AI-generated content and preserving standards of excellence in pharmaceutical research and practice requires a proactive strategy of constant learning and community participation.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10791078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to access of maternal health commodities among pregnant women in public health facilities in Ubungo Municipal Council, Tanzania","authors":"Doris Mollel, G. Kagashe, D. Asingizwe, Stany Banzimana, S. M. Maru, François Niragire","doi":"10.1080/20523211.2023.2300457","DOIUrl":"https://doi.org/10.1080/20523211.2023.2300457","url":null,"abstract":"","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139442776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis","authors":"Ola Yakti, D. Al-Badriyeh, M. Rijims, Mohammed Abdelaal, O. Alsoukhni, M. Al Hail, P. Abdulrouf, Wessam El-Kassem, Fouad F. Abounahia, R. Kaddoura, D. Abushanab","doi":"10.1080/20523211.2023.2291508","DOIUrl":"https://doi.org/10.1080/20523211.2023.2291508","url":null,"abstract":"","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139452713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of prices, availability and affordability of essential medicines in Juba County, South Sudan.","authors":"Justin Deng, Augustino Ting Mayai, Egide Kayitare, Theoneste Ntakirutimana, Omary Swallehe, Thomas Bizimana","doi":"10.1186/s40545-023-00675-5","DOIUrl":"10.1186/s40545-023-00675-5","url":null,"abstract":"<p><strong>Background: </strong>Access to safe, effective, affordable, and high-quality medications has been included in the Sustainable Development Goals (SDGs) of the United Nations as a crucial step towards attaining universal health coverage. Access to medicines is a fundamental human right. If medicines are accessible and affordable, they save lives by reducing mortality and morbidity associated with acute and chronic diseases. WHO recommends that all countries voluntarily reach the minimum target of 80% availability of medicines by 2025. The primary purpose of this research is to assess access to essential medicines in Juba County, South Sudan.</p><p><strong>Methods: </strong>This study was undertaken using the standard World Health Organization/Health Action International Organization (WHO/HAI) approach for surveying the prices, availability, and affordability of medicines. A survey was conducted in six payams of Juba County, South Sudan, and 55 health facilities were assessed.</p><p><strong>Results: </strong>Prices for generic medicines were better in faith-based health facilities with a median price ratio of 1.95. Private pharmacies and private clinics had MPRs of 4.64 and 4.32, respectively. Local prices were high compared to International referent prices. Availability of medicines was highest in the faith-based health facilities (65.5%) and slightly lower in private pharmacies (55.4%), private clinics (57.7%) and public (50.4%) sectors. Most of the surveyed medicines were unaffordable. The medicines needed to treat non-communicable diseases cost up to 33.7-day wages for one full course of treatment.</p><p><strong>Conclusions: </strong>In South Sudan, medicines are poorly available in all sectors. Medicines are affordable in the public sector but Most medicines are unaffordable in private pharmacies, private clinics and faith-based health facilities. Poor medicines availability in the public sector contributes to the overall unaffordability of medicines in all the other sectors.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10757353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139074408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}